Bioquell has reported a strong set of interim results, with reported revenues +9% to £15.7m. Excluding Defence sales and the disposed-of Airflow business, like-for-like revenues increased by 15% on a constant currency basis. In light of the strong H1 showing and positive commentary over the outlook, we upgrade our EPS forecasts by 10% this year and 13% in FY19, the fourth double digit upgrades we have made in the last 12m. The growth opportunity is by no means exhausted however and we see the FY19 rating of under 10x EV/EBITDA as extremely undemanding.
